Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning

Bone Marrow Transplantation

Volumn 45, Issue 4, 2010, Pages 689-693

  Willems, E ^a,b   Baron, F ^a,b   Seidel, L ^b   Frere P ^a,b   Fillet, G ^a,b   Beguin, Y ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

GVHD; Hematopoietic cell transplantation; Nonmyeloablative; Thrombotic microangiopathy

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; THROMBOTIC THROMBOCYTOPENIC PURPURA; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOTIC MICROANGIOPATHIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77950618826     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.230     Document Type: Article

References (23)

1. Batts ED, Lazarus HM. Diagnosis and treatment of transplantation- associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709-719.
2. Kojouri K, George JN. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 2007; 19: 148-154. (Pubitemid 46204355)
3. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
4. Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24: 4150-4157. (Pubitemid 46622292)
5. Baron F, Sandmaier BM, Storer BE, Maris MB, Langston AA, Lange T et al. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant 2007; 13: 1041-1048. (Pubitemid 47215560)
6. Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E et al. Unrelated donor granulocyte colonystimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006; 12: 454-465.
7. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993-2003. (Pubitemid 46211379)
8. Baron F, Petersdorf EW, Gooley T, Sandmaier BM, Malkki M, Chauncey TR et al. What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant 2009; 15: 580-588.
9. Baron F, Sandmaier BM. Nonmyeloablative Transplantation. In: Soiffer RJ (ed). Hematopoietic Stem Cell Transplantation. Humana Press: Totowa, 2008, pp 349-374.
10. Castermans E, Baron F, Willems E, Schaaf-Lafontaine N, Meuris N, Gothot A et al. Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica 2008; 93: 240-247. (Pubitemid 351397712)
11. Baron F, Baudoux E, Frere P, Tourqui S, Schaaf-Lafontaine N, Herens C et al. Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC. Bone Marrow Transplant 2003; 32: 829-834. (Pubitemid 38455950)
12. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571-575. (Pubitemid 41001631)
13. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
14. Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben Bassat I, Nagler A. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced. Biol Blood Marrow Transplant 2004; 10: 484-493. (Pubitemid 38772002)
15. Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006; 81: 525-531.
16. Holler E, Kolb HJ, Hiller E, Mraz W, Lehmacher W, Gleixner B et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989; 73: 2018-2024. (Pubitemid 19145140)
17. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27: 641-646. (Pubitemid 32401463)
18. Daly AS, Hasegawa WS, Lipton JH, Messner HA, Kiss TL. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apher Sci 2002; 27: 3-12.
19. Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006; 82: 638-644. (Pubitemid 44395233)
20. Ruutu T, Hermans J, Niederwieser D, Gratwohl A, Kiehl M, Volin L et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 1112-1119. (Pubitemid 35025977)
21. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359: 2078-2083. (Pubitemid 34680972)
22. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44: 294-304. (Pubitemid 38236394)
23. Hale GA, Bowman LC, Rochester RJ, Benaim E, Heslop HE, Krance RA et al. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant 2005; 11: 912-920. (Pubitemid 41645644)